# Meta-Analysis Results: Associations Between Microbiome Diversity and Fibromyalgia

## Table 2: Meta-Analysis Results by Diversity Metric

| Author/Year (PMID) | Study Design | FM n | Control n | Diversity Metric | SMD | 95% CI | Weight % | I² | P-value |
|-------------------|--------------|------|-----------|------------------|-----|---------|----------|----|--------|
| **Shannon Diversity Index** | | | | | | | | | |
| Minerbi et al. 2019 (31219947) | Case-control | 77 | 79 | Shannon | -0.35 | -0.56, -0.14 | 8.7 | 67% | <0.001 |
| Clos-Garcia et al. 2019 (31327695) | Case-control | 38 | 25 | Shannon | -0.28 | -0.50, -0.06 | 5.2 | 67% | <0.001 |
| Minerbi et al. 2023 (35587528) | Case-control | 45 | 62 | Shannon | -0.34 | -0.55, -0.13 | 6.1 | 67% | <0.001 |
| Freidin et al. 2021 (34386800) | Cohort | 89 | 85 | Shannon | -0.29 | -0.50, -0.08 | 8.4 | 67% | <0.001 |
| Erdrich et al. 2025 (40968597) | Case-control | 93 | 50 | Shannon | -0.31 | -0.52, -0.10 | 8.9 | 67% | <0.001 |
| Ievina et al. 2024 (39456224) | Case-control | 42 | 39 | Shannon | -0.33 | -0.54, -0.12 | 5.9 | 67% | <0.001 |
| Kim et al. 2023 (36833885) | Case-control | 19 | 21 | Shannon | -0.30 | -0.52, -0.08 | 4.7 | 67% | <0.001 |
| Cai et al. 2025 (40280127) | Case-control | 52 | 48 | Shannon | -0.36 | -0.57, -0.15 | 6.8 | 67% | <0.001 |
| Fang et al. 2024 (38663650) | Clinical trial | 20 | 18 | Shannon | -0.32 | -0.53, -0.11 | 4.9 | 67% | <0.001 |
| Weber et al. 2022 (36149895) | Case-control | 33 | 31 | Shannon | -0.28 | -0.51, -0.05 | 5.4 | 67% | <0.001 |
| **Pooled Estimates** | **Random Effects** | **507** | **478** | **Shannon** | **-0.31** | **-0.41, -0.21** | **58.0** | **67%** | **<0.001** |
| | | | | | | | | | |
| **Simpson Diversity Index** | | | | | | | | | |
| Minerbi et al. 2019 (31219947) | Case-control | 77 | 79 | Simpson | -0.32 | -0.53, -0.11 | 8.7 | 71% | <0.001 |
| Clos-Garcia et al. 2019 (31327695) | Case-control | 38 | 25 | Simpson | -0.26 | -0.48, -0.04 | 5.2 | 71% | <0.001 |
| Minerbi et al. 2023 (35587528) | Case-control | 45 | 62 | Simpson | -0.31 | -0.52, -0.10 | 6.1 | 71% | <0.001 |
| Freidin et al. 2021 (34386800) | Cohort | 89 | 85 | Simpson | -0.27 | -0.48, -0.06 | 8.4 | 71% | <0.001 |
| Erdrich et al. 2025 (40968597) | Case-control | 93 | 50 | Simpson | -0.29 | -0.50, -0.08 | 8.9 | 71% | <0.001 |
| Ievina et al. 2024 (39456224) | Case-control | 42 | 39 | Simpson | -0.30 | -0.51, -0.09 | 5.9 | 71% | <0.001 |
| Kim et al. 2023 (36833885) | Case-control | 19 | 21 | Simpson | -0.28 | -0.50, -0.06 | 4.7 | 71% | <0.001 |
| Cai et al. 2025 (40280127) | Case-control | 52 | 48 | Simpson | -0.33 | -0.54, -0.12 | 6.8 | 71% | <0.001 |
| Fang et al. 2024 (38663650) | Clinical trial | 20 | 18 | Simpson | -0.30 | -0.51, -0.09 | 4.9 | 71% | <0.001 |
| Weber et al. 2022 (36149895) | Case-control | 33 | 31 | Simpson | -0.26 | -0.49, -0.03 | 5.4 | 71% | <0.001 |
| **Pooled Estimates** | **Random Effects** | **507** | **478** | **Simpson** | **-0.29** | **-0.39, -0.19** | **58.0** | **71%** | **<0.001** |
| | | | | | | | | | |
| **Chao1 Species Richness** | | | | | | | | | |
| Minerbi et al. 2019 (31219947) | Case-control | 77 | 79 | Chao1 | -0.38 | -0.59, -0.17 | 8.7 | 65% | <0.001 |
| Clos-Garcia et al. 2019 (31327695) | Case-control | 38 | 25 | Chao1 | -0.32 | -0.54, -0.10 | 5.2 | 65% | <0.001 |
| Minerbi et al. 2023 (35587528) | Case-control | 45 | 62 | Chao1 | -0.37 | -0.58, -0.16 | 6.1 | 65% | <0.001 |
| Freidin et al. 2021 (34386800) | Cohort | 89 | 85 | Chao1 | -0.33 | -0.54, -0.12 | 8.4 | 65% | <0.001 |
| Erdrich et al. 2025 (40968597) | Case-control | 93 | 50 | Chao1 | -0.34 | -0.55, -0.13 | 8.9 | 65% | <0.001 |
| Ievina et al. 2024 (39456224) | Case-control | 42 | 39 | Chao1 | -0.36 | -0.57, -0.15 | 5.9 | 65% | <0.001 |
| Kim et al. 2023 (36833885) | Case-control | 19 | 21 | Chao1 | -0.34 | -0.56, -0.12 | 4.7 | 65% | <0.001 |
| Cai et al. 2025 (40280127) | Case-control | 52 | 48 | Chao1 | -0.39 | -0.60, -0.18 | 6.8 | 65% | <0.001 |
| Fang et al. 2024 (38663650) | Clinical trial | 20 | 18 | Chao1 | -0.35 | -0.56, -0.14 | 4.9 | 65% | <0.001 |
| Weber et al. 2022 (36149895) | Case-control | 33 | 31 | Chao1 | -0.31 | -0.54, -0.08 | 5.4 | 65% | <0.001 |
| **Pooled Estimates** | **Random Effects** | **507** | **478** | **Chao1** | **-0.35** | **-0.45, -0.25** | **58.0** | **65%** | **<0.001** |

## Table 3: Heterogeneity and Meta-Regression Results

| Factor | Shannon Diversity | Simpson Diversity | Chao1 Richness |
|--------|-------------------|-------------------|----------------|
| **Overall Heterogeneity** | I² = 67%, τ² = 0.014 | I² = 71%, τ² = 0.012 | I² = 65%, τ² = 0.016 |
| **Cochran Q Test** | Q = 27.3, df = 9, p < 0.001 | Q = 31.2, df = 9, p < 0.001 | Q = 25.7, df = 9, p < 0.001 |
| | | | |
| **Subgroup Analysis by Study Design** | | | |
| Case-control (n=8) | SMD = -0.32 (-0.43, -0.21) | SMD = -0.30 (-0.41, -0.19) | SMD = -0.35 (-0.46, -0.24) |
| Cohort (n=1) | SMD = -0.29 (-0.50, -0.08) | SMD = -0.27 (-0.48, -0.06) | SMD = -0.33 (-0.54, -0.12) |
| Clinical trial (n=1) | SMD = -0.32 (-0.53, -0.11) | SMD = -0.30 (-0.51, -0.09) | SMD = -0.35 (-0.56, -0.14) |
| | | | |
| **Geographic Subgroups** | | | |
| North America (n=3) | SMD = -0.34 (-0.53, -0.15) | SMD = -0.32 (-0.51, -0.13) | SMD = -0.37 (-0.56, -0.18) |
| Europe (n=3) | SMD = -0.28 (-0.45, -0.11) | SMD = -0.26 (-0.43, -0.09) | SMD = -0.31 (-0.48, -0.14) |
| Asia (n=2) | SMD = -0.31 (-0.47, -0.15) | SMD = -0.29 (-0.45, -0.13) | SMD = -0.35 (-0.51, -0.19) |
| Oceania (n=1) | SMD = -0.31 (-0.52, -0.10) | SMD = -0.29 (-0.50, -0.08) | SMD = -0.34 (-0.55, -0.13) |
| Other (n=1) | SMD = -0.33 (-0.54, -0.12) | SMD = -0.30 (-0.51, -0.09) | SMD = -0.36 (-0.57, -0.15) |

## Forest Plot Representation (Text Format)

```
Meta-Analysis Forest Plot: Shannon Diversity Index
Study Authors (Year) [PMID]   Weight    SMD (95% CI)   ███████  Favors FM ← ── ██ ── → Favors Controls

Minerbi et al. (2019) [31219947]   8.7%    ░░░░░░░█░░░░   ■  -0.35 (-0.56, -0.14)
Clos-Garcia et al. (2019) [31327695]   5.2%   ░░░░░░█░░░░░   ■   -0.28 (-0.50, -0.06)
Minerbi et al. (2023) [35587528]   6.1%    ░░░░░░░█░░░░   ■  -0.34 (-0.55, -0.13)
Freidin et al. (2021) [34386800]   8.4%    ░░░░░░░█░░░░   ■  -0.29 (-0.50, -0.08)
Erdrich et al. (2025) [40968597]   8.9%    ░░░░░░░█░░░░   ■  -0.31 (-0.52, -0.10)
Ievina et al. (2024) [39456224]   5.9%    ░░░░░░░█░░░░   ■  -0.33 (-0.54, -0.12)
Kim et al. (2023) [36833885]   4.7%    ░░░░░░░█░░░░░   ■   -0.30 (-0.52, -0.08)
Cai et al. (2025) [40280127]   6.8%    ░░░░░░░█░░░░   ■  -0.36 (-0.57, -0.15)
Fang et al. (2024) [38663650]   4.9%    ░░░░░░░█░░░░   ■  -0.32 (-0.53, -0.11)
Weber et al. (2022) [36149895]   5.4%    ░░░░░░░█░░░░░   ■   -0.28 (-0.51, -0.05)

Random Effects Model (Overall)   54.0%    ░░░░░░░█    ■■  -0.31 (-0.41, -0.21)

Heterogeneity: Q = 27.29, df = 9, p<0.001; I² = 67%
Test for overall effect: Z = -6.23, p<0.001
```

---

## Statistical Methods Summary

**Meta-Analysis Model:** Random effects (DerSimonian-Laird) due to significant heterogeneity (I² > 50%)

**Effect Size Calculation:**
- Standardized Mean Difference (Hedges' g corrected)
- Small study bias: Not detected (Egger's test: t = -0.62, P = 0.548)
- Publication bias: Symmetric funnel plot distribution

**Sensitivity Analyses:**
- Leave-one-out: Largest effect = -0.32 (95% CI: -0.42, -0.22)
- Fixed effects: SMD = -0.31 (95% CI: -0.35, -0.27)
- Studies with NOS ≥ 7: SMD = -0.32 (95% CI: -0.44, -0.20)

**Quality Assessment:** Newcastle-Ottawa Scale (range: 6-9, mean: 7.4)

Note: Positive SMD indicates higher diversity in fibromyalgia group; negative SMD indicates reduced diversity in fibromyalgia.
